Clinical Trial

Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors

Adding Decades of Public Company and Board Expertise as Prenetics Readies for Expansion into Consumer Health and WellnessLOS ANGELES, July…

2 years ago

Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION1 JULY 2024 at 15:15 EEST         Inside information: Orion and MSD Announce Mutual Exercise…

2 years ago

Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid…

2 years ago

Spectral AI Joins Russell Microcap® Index

DALLAS, July 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence…

2 years ago

Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327

Results demonstrate efficacy on bacterial growth in participants injected with RECCE® 327 (R327) at the highest tested dose of 4,000mgNo…

2 years ago

Korro Joins the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes

CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing…

2 years ago

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we,…

2 years ago

Biora Therapeutics Announces Positive Clinical Trial Results for BT-600

Drug-device combination leverages Biora’s NaviCap™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis…

2 years ago

Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on…

2 years ago